Gin Hwa Biotech Listed on Emerging Stock Board, Advancing Toward a World-Class CDMO Manufacturer

With a foundation in traditional herbal medicine and the integration of Western raw materials, Gin Hwa Biotech upholds the principle of "ensuring food safety and maintaining client credibility" through its one-stop CDMO (Contract Development and Manufacturing Organization) services. Today (12th), the company officially launched its listing on Taiwan's Emerging Stock Board, with a reference price of NT$65 per share, under the guidance of Yuanta Securities.

A Trusted OEM Partner for Health Supplements in Taiwan

Founded in 2019, Gin Hwa Biotech (stock code: 7806) is a specialized OEM manufacturer for health supplements. With a seasoned R&D team comprised of professionals in both Eastern and Western medicine, the company integrates traditional Chinese herbal ingredients with Western raw materials. Gin Hwa Biotech assists clients through every stage—from market analysis, formulation design, raw material selection, prototyping, packaging design, mass production, quality testing, training, to marketing planning. Offering OEM, ODM, and complete one-stop CDMO services, Gin Hwa Biotech strives to deliver the most suitable product formulations tailored to each client, becoming the most trusted professional contract manufacturer in the health supplement industry.

Meeting Global Demand with Professionalism and Innovation

As the world population ages and preventive healthcare becomes a global trend, the demand for health supplements has surged. In 2023, the global health and nutrition market exceeded USD 860 billion and is projected to surpass USD 1 trillion by 2026, with the Asia-Pacific region leading growth and expected to account for over 30% of the market.

Positioning itself from inception as a world-class CDMO rather than developing its own brand, Gin Hwa Biotech leverages its strong foundation in herbal extraction and integrates intelligent automation and green manufacturing to serve its brand clients. Committed to its core value of “co-guarding food safety and client trust,” Gin Hwa enforces strict standards in raw material testing, production control, personnel, and environmental management. Operating under the principles of integrity, discipline, innovation, quality, and partnership, Gin Hwa Biotech delivers safe and effective Made-in-Taiwan products and aims to create win-win relationships with clients.

Diversified Dosage Forms and Competitive Differentiation

Gin Hwa Biotech offers a comprehensive range of dosage forms—from extract, concentrate, liquids, pastes, powders, tablets, capsules, softgels, jellies, tea bags to functional beverages—and has quickly risen to industry leadership. With a robust customized formulation database, the company has developed over 1,000 supplement products to date. It currently holds two TFDA-certified health food claims ("Health Food Mark"), including:

• TFDA A00440: Helps regulate blood lipids

• TFDA A00451: Helps regulate blood sugar

Gin Hwa is investing in new clinical studies to expand its TFDA-certified product line, aiming to enhance product differentiation and efficacy, thus strengthening international competitiveness for its clients.

Continued Growth and International Expansion

With a PhD- and master-level R&D team, Gin Hwa Biotech has earned the trust of numerous domestic and international health supplement companies. Over the past five years, its business performance has shown significant year-over-year growth. In 2024, the company completed its overseas market deployment, increased R&D investment, accelerated the development of new products and ingredients, and formed an international marketing team.

To support its global expansion, Gin Hwa Biotech has been approved for funding under the Ministry of Economic Affairs' "Invest Taiwan" initiative. The investment includes the construction of a new plant, advanced R&D laboratories, and a more automated, intelligent, and eco-friendly production line, expected to significantly boost revenue upon launch.

As of now, Gin Hwa Biotech has a paid-in capital of NT$238.6 million. In 2023, it recorded NT$404 million in revenue with NT$82 million in net profit after tax and an EPS of NT$6.15. For the first two quarters of 2024, revenue reached NT$211 million, with net profit of NT$38 million and an EPS of NT$1.84.

With global demand for health supplements on the rise, Gin Hwa Biotech is well positioned for continued growth and long-term success.